Bull Hedging
  • Politics
  • Stocks
  • Business
  • Investing
  • Politics
  • Stocks
  • Business
  • Investing

Bull Hedging

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

by admin June 4, 2025
June 4, 2025
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

previous post
Uber delivery chief Gore-Coty is leaving after almost 13 years at ride-hailing company
next post
Adam Rozencwajg: Gold Stock Gains, Silver and Uranium Prices — Plus PGMs Bull Case

Related Posts

Earthwise Advertising & Investor Awareness Campaign

August 31, 2025

Editor’s Picks: Gold Price Passes US$2,950, Trump Promises...

February 23, 2025

$2.85m Placement in Conjunction with 815Koz AuEq Acquisition

April 14, 2025

Noble Minerals Acquires a Property with Significant Uranium,...

January 18, 2025

Alpha Test Program 6 Continues to Deliver Improved...

April 8, 2025

Clarification to Offtake & Distribution Agreement

May 1, 2025

5 Biggest Pharmaceutical ETFs in 2025

May 7, 2025

Crypto Market Recap: Bitcoin Hashrate Drops, Coinbase Shares...

June 27, 2025

Stonegate Capital Partners Initiates Coverage on Heliostar Metals...

September 27, 2025

Quimbaya Gold Announces Strategic Private Placement of up...

May 29, 2025

Recent Posts

  • The Real Drivers of This Market: AI, Semis & Robotics
  • S&P 500 Breaking Out Again: What This Means for Your Portfolio
  • Chip Roy says Democratic Party taking its ‘dying breaths’
  • Hamas transfers coffin of dead hostage to Israel, IDF confirms
  • GOP bill targets United Nations’ global carbon ‘tax scheme’

Recent Comments

No comments to show.

About Us

About Us

Design Magazine

Welcome to Design Magazine. Follow us for daily & updated design tips, guide and knowledge.

Stay Connect

Facebook Twitter Instagram Pinterest Youtube Email

Recent Posts

  • The Real Drivers of This Market: AI, Semis & Robotics

    October 21, 2025

  • S&P 500 Breaking Out Again: What This Means for Your Portfolio

    October 21, 2025

  • Chip Roy says Democratic Party taking its ‘dying breaths’

    October 21, 2025

  • Hamas transfers coffin of dead hostage to Israel, IDF confirms

    October 21, 2025

  • GOP bill targets United Nations’ global carbon ‘tax scheme’

    October 21, 2025

  • US to expedite nuclear-powered subs to Australia that will sit near China’s doorstep

    October 21, 2025

Editors’ Picks

  • 1

    Small Caps are Set to Skyrocket in 2025—Here’s What You Need to Know

    December 12, 2024
  • 2

    Ad revenue should stabilize for media companies in 2025 — if they have sports

    December 31, 2024
  • 3

    Trump leaves China guessing what his next move is with unusual inauguration invitation

    December 15, 2024
  • 4

    Lead Price Forecast: Top Trends for Lead in 2025

    January 11, 2025
  • 5

    Uranium Price Forecast: Top Trends That Will Affect Uranium in 2025

    December 19, 2024
  • 6

    Zinc Stocks: 4 Biggest Canadian Companies in 2025

    January 15, 2025
  • 7

    Trudeau declares himself ‘proud feminist’ after lamenting Harris loss to Trump as setback for women

    December 13, 2024
Promotion Image

banner

Categories

  • Business (580)
  • Investing (2,234)
  • Politics (2,726)
  • Stocks (854)
  • About us
  • Contacts
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting

Disclaimer: bullhedging.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2025 bullhedging.com | All Rights Reserved